Healthcare Medical Pharmaceutical Directory.com
- Retail pharmacies dispensing more complex therapies aligned with specialty pharmacy programs; consumer / patient cost sharing of the pharmacy benefit continues to increase
- Retail store-based medical clinics increasing and providing access to care but competing against physician practices
- Retail and PBM pharmacy providers are closely monitoring Amazon and its PillPack unit as they ramp up their clinical and commercial operations as well as their marketing initiatives
... See how retail pharmacy-based healthcare clinics are changing healthcare delivery in the United States, read the article below for insights ...
Specialty Pharmacy Profile
Specialty pharmacy typically involves advanced therapies and complex patient types. Therapies dispensed are often referred to as “biologics”or “large molecule” agents; they can also be conventional oral or injectable products for patients with highly specialized care needs. Oncology is a cornerstone of the specialty pharmacy sector. The high level of patient care involved coupled with the high cost, advanced pharmaceuticals required are well suited to the abilities of these providers. As more biologicals reach the marketplace for other advanced patient care conditions, oncology / specialty pharmacy protocols are readily transferable to them.
Specialty drugs and their patients can be broadly categorized as having a combination of these attributes:
- Complex to manufacture and distribute; they require special handling and administration
- Usually injectable but may be oral; injectables can be self-administered or administered by a clinician
- Due to being advanced/specialized, they are costly and taken by a smaller portion of the population
- Specialty pharmacy patients require more care and are more challenging cases for clinicians to treat
A large portion of specialty pharmacy patients are covered via Medicare. While the number of specialty pharmacy patients is relatively small in terms of the overall population, the cost of the medications they require make up a very large portion of total drug spend in both commercial and government healthcare or pharmacy benefit plans. Specialty pharmacy therapies can run from $10,000 to $100,000 in annual cost. Depending upon the therapy and the benefit program it is featured in, the product may be covered through the medical or the pharmacy benefit. Besides storing, shipping specialty products and counseling patients, specialty pharmacies usually spend considerable time and resources verifying coverage of patients and identifying the most appropriate benefit ( medical or pharmacy ) to adjudicate the claim through.
When patients self-inject specialty drugs or take them orally, the pharmacy benefit associated with their health plan often provides coverage through the use of a PBM. When a clinician administers specialty drug therapies (through an IV or injection), the product is usually covered by the medical benefit.
Buy And Bill Pharmaceutical Procurement And Reimbursement Practices
Clinicians administering injectable / intravenous specialty pharmaceuticals under the medical benefit purchase the products and then are reimbursed by payers in an arrangement called “buy and bill". Buy and bill has been a controversial business arrangement. Although it has been utilized for years, there have been issues as to how much the product cost when the clinician procured the product and what the clinician actually charged the patient and payer.
Clinicians would substantially markup products in buy and bill arrangements, especially in oncology. Payers (commercial and government) have put limits on the percentage of markup they will allow physicians to charge them but fixed price arrangements are increasingly becoming the standard. Hospital outpatient facilities also acquire specialty therapies through negotiating their own terms with manufacturers and bill the patients / payers for their administration.
Specialty Pharmacy Operating Models
Specialty pharmacies and their services operate through different models. Some are organized as "closed door" pharmacy facilities which do not have storefronts or "walk-in" business, some are operating units of PBMs in conjunction with mail order facilities, others are administered through retail pharmacies equipped and staffed to provide specialty pharmacy services. Other variations include hybrid specialty pharmacy business models which are combinations of specialty pharmacy and infusion centers or specialty pharmacies supporting home infusion providers and / or long term care facilities. Depending on the size of the organization and therapies offered, they can operate as a hub pharmacy for a manufacturer plus have multiple locations servicing regional or metropolitan areas throughout the nation.
The leading therapeutic categories dispensed via specialty pharmacy venues are:
Specialty Pharmacy Reimbursement And Market Access
Reimbursement in the specialty pharmacy sector can be complex. Depending on the patient, medication, provider and the plan(s) involved; a claims adjudication pathway may resemble a retail pharmacy claim or it could involve separate charges for therapies, per diem payments for supplies, equipment, pharmacy services, non-nursing care services, shipping and then separate payments for nursing care. Home infusion is typically paid for under the medical benefit but overall specialty pharmacy reimbursement can be through the pharmacy or the medical benefit depending on the patient, therapy, point-of-care and how the patient's insurance plan (or PBM) chooses to align the payments based on the benefit design.
Pharmaceutical manufacturers and other product producers have to account for the nuances of the specialty pharmacy service sector in their market access strategy and tactics. Failure to accommodate the unique payer and service attributes within it can greatly reduce or even lock out a product from being used as contracting, payer support and reimbursement is not in place and / or a promotional pull-through framework and messaging is not aligned with the channel.
Retail and Mail Order Pharmacy Market Sector Overview...
Retail Pharmacy Profile
The pharmacy sector has completely remade itself since 2000. The chain drugstore market is dominated by two players, Walgreens and CVS; Rite Aid is in a much lesser scale position and regional pharmacy chain Fred’s has entered final bankruptcy proceedings. There is speculation about Walgreens either going private with help from private equity ally KKR or perhaps being acquired by Amazon, Kroger or Walmart:
As for the mass merchandiser sector of retail pharmacy, Walmart ( NYSE: WMT ), Sam’s Club ( part of Walmart Inc/ ) and Target ( NYSE:TGT ) own this market but it is important to remember CVS owns and operates the pharmacy departments in all Target stores. Costco ( NYSE: COST ) is coming on strong as a player in the consumer and patient care provider segment through augmenting their retail pharmacy units with hearing, optical and other healthcare services, including pharmacy benefit management and mail order pharmacy.
Leading grocery chains like Kroger ( NYSE: KR ) and Albertsons ( private equity owned ) are the dominant grocery-based pharmacies; the larger regional players in grocery pharmacy include HEB ( privately held ) and Publix ( privately held ).
In September, 2019, courts approved CVS Health's acquisition of Aetna. CVS acquired Aetna to widen its business model; together they widen their position in pharmacy and health insurance. The CVS Health / Aetna tandem will have wide impact across multiple healthcare sectors in 2020 and moving forward with such entities as employee benefit consultants, PBMs, MCOs, physician practice groups, health systems and retail, mail order and specialty pharmacy. Checkout these links for more details about how one of the largest chain drugstore retailers and pharmacy benefit managers in the United States transformed their business model through acquiring one of the largest and oldest health insurance / managed care organizations in the country:
Compounding Pharmacy Profile
Compounding pharmacies are distinctly different service providers. They support healthcare systems, home infusion companies, hospitals, long term care facilities and physician/clinic-based care providers. Their business is based on more specialized products which they produce on a contract basis for various providers; those with high volume, advanced capabilities are registered as "503Bs" which align them closer to "manufacturer" status.
An assortment of State and Federal regulators have expressed concern about and seek clarification on the status of compounding pharmacies as being manufacturers of product versus pharmacy providers. This originates from the New England Compounding Center's (NECC) safety violations which produced defective product that caused deaths and hospitalizations for patients who contracted meningitis from their administration. NECC was affiliated with a larger compounding pharmacy entity, Ameridose. Both commercial enterprises have ceased to operate. There is ongoing dialogue between government, provider and healthcare product manufacturers as to how compounding pharmacies will be categorized and subsequently regulated moving forward.
In October, '15 AmerisourceBergen acquired PharMEDium for $2.58 billion; this fortified their position in large scale, institutional pharmacy services. Margins within the compounding pharmacy unit are substantially higher than the drug wholesaling business. PharMEDium is expected to ramp up quickly during to fulfill opportunities via AmerisourceBergen channels and grow the legacy PharMEDium book of business. With the exit of Cantrell from the marketplace, PharMedium has the leading presence in compounding pharmacy but an FDA permanent injunction against them in 2019 has brought more scrutiny to bear from Federal and State regulators across the nation to compounding pharmacies and best practices.
Mail Order Pharmacy Profile
While mail order and specialty pharmacy sectors are a comparatively fragmented sector, the leaders are CVS / Aetna, Cigna / ExpressRx, United Healthcare / OptumRx, Anthem BCBS / Ingenio Rx and AllianceRx Walgreens Prime. One of the largest merger and acquisition deals regardless of industry was Cigna acquiring Express Scripts (now known as ExpressRx) for $54 billion in 2018. The ramping up of Amazon and its PillPack online mail order pharmacy enterprise progressing into 2020 and beyond will be a viable contender as its marketing initiatives take shape and its issues with SureScripts resolved via a commercial agreement or litigation decision.
Mail order pharmacies offer home delivery of prescription medications which are maintenance therapies (blood pressure, cholesterol, diabetes, oral contraceptives, etc.). In addition, they often provide specialty pharmacy services for advanced injectable and biological therapies. A number of managed care organizations, PBMs and the larger retail pharmacy chains operate their own mail order pharmacies. Key managed care attributes include:
- Advanced clinical/financial reporting for payers/plans/providers
- Convenience for members not having time or proximity to visit retail pharmacies for prescription
- Economical prescription drug access for consumers/patients based on lower days supply copays
- Rigid formulary management to control employer / prescription plan payer expenses
- Rapid, large scale brand to generic conversion upon brand expiration which cuts costs
- Specialty pharmacy service attributes for advanced therapies
... A list of Mass Merchandiser Pharmacies ...
... A list of Mail Order Pharmacies ...
... As Amazon expands its business into the healthcare sector, pharmacy retailers may find themselves under siege ...
... This is a list of Retail Pharmacies; scroll down for Mass Merchandiser Pharmacies, Compounding Pharmacies, Mail Order Pharmacies, Specialty Pharmacies plus pharmacy market sector profile and trends ...
... A list of Compounding Pharmacies...
... Find out more about Compounding Pharmacies, visit the learning resource below ...
... A list of Specialty Pharmacies ...
... Multiple factors trigger change and innovation in pharmacy; new products and other developments frequently occur and a growing biosimilar pharmaceutical sector are catalysts for more advancements ...
...A healthcare marketing resource for pharmaceutical, medical device, technology, patient care, programs and services spanning strategy, digital marketing, trends and managed care / market access: a global community of users from 50+ nations...